9M 2023 Financial Performance

9M 2023: APPENDIX Volume growth in the U.S. robust, but Trintellix still impacted by post-pandemic effects (NRx Count) 31 75,000 50,000 25,000 ONCE-MONTHLY Abilify Maintena (aripiprazole) prolonged-release suspension for injection 400,000 Trintellix +1% -1% -3% vortioxetine +8% +8% +8% 200,000 0 0 Q3.18 Q3.19 Q3.20 Q3.21 Q3.22 Q3.23 Q3.18 Q3.19 Q3.20 Q3.21 Q3.22 Q3.23 +15% 200,000 REXULTI 100,000 +14% +8% 600 vyepti 400 (eptinezumab-jjmr) 200 +29% +10% 0 Q3.18 Q3.19 Q3.20 Q3.21 Q3.22 Q3.23 Q3.20 Q3.21 Q3.22 Q3.23 Source: Symphony Health (ref Bloomberg). NRx: new prescription Lundbeck

View entire presentation